Revumenib: Key Considerations Before and During Treatment

　　The US FDA prescribing information does not include formal contraindications for revumenib.This should not be interpreted as suitability for all patients with leukemia.Treatment decisions should account for cardiac baseline status,reproductive plans,concomitant medications,and individual risk of adverse events.

　　QTc prolongation and electrolyte disturbances.​Revumenib can prolong the QTc interval,which in severe cases may lead to torsades de pointes.Treatment should not be initiated in patients with a baseline QTcF exceeding 450 ms.Electrolyte abnormalities such as hypokalemia and hypomagnesemia further increase arrhythmic risk and should be corrected before treatment and monitored throughout.

　　Pregnancy and reproductive risk.​Based on its mechanism of action,revumenib may cause embryo-fetal harm.Females of reproductive potential should verify pregnancy status prior to initiation and use effective contraception.Male patients with partners of reproductive potential should also be counseled regarding potential risk.

　　Lactation.​It is not known whether revumenib is excreted in human milk.The US label advises against breastfeeding during treatment and for one week after the final dose.

　　Concomitant medications and drug interactions.​Revumenib is primarily metabolized by CYP3A4,and coadministration with certain agents may alter its exposure.Strong CYP3A4 inhibitors can increase revumenib concentrations and require dose adjustment.Concomitant use of strong or moderate CYP3A4 inducers should be avoided per the label.Drugs known to prolong the QT interval should also be avoided where possible,with intensified ECG monitoring if coadministration is unavoidable.

　　Management of serious adverse reactions.​Revumenib carries a risk of differentiation syndrome,which may present with fever,dyspnea,hypotension,rapid weight gain,and edema.Hepatic dysfunction,infection,and hematologic changes also warrant attention.Severe toxicity may require treatment interruption,dose modification,or permanent discontinuation.